Dov Goldstein

Dov Goldstein has a diverse work experience that spans over several companies and roles. Dov currently holds the position of Chief Financial Officer at BioAge Labs, a position they have held since November 2021. Prior to that, they worked as a Director at NeuBase Therapeutics, Inc. starting in July 2019. Dov also served as the Chief Financial Officer and Chief Business Officer at Indapta Therapeutics from August 2020 to November 2021. Dov has also worked as a Director at RIGImmune from January 2020 to June 2021. Before their roles in various companies, they were a Partner at Aisling Capital from November 2009 to November 2019, and a Principal at the same company from September 2006 to November 2009. During this time, they also served as a Director at ADMA Biologics, Inc. from May 2008 to November 2019, as well as at Esperion - The Lipid Management Company from May 2008 to May 2019. Dov was the CFO at Schrodinger Therapeutics from November 2017 to May 2018, and previously held the same position at Vicuron Pharmaceuticals from July 2000 to November 2005. Dov started their career as the Director of Venture Analysis at HealthCare Ventures LLC from August 1998 to July 2000.

Dov Goldstein began their education at Stanford University, where they pursued a Bachelor of Science (BS) degree in Biology/Biological Sciences, General, from 1986 to 1990. After completing their undergraduate studies, they enrolled at the Yale School of Medicine from 1990 to 1995, where they obtained their Doctor of Medicine (M.D.) degree. Following their medical education, Goldstein furthered their academic journey at Columbia Business School from 1996 to 1998. During their time at Columbia, they earned a Master of Business Administration (MBA) degree with a specialization in Finance, General.